Bonnie Anderson CEO

A message from Veracyte's CEO

To Our Friends and Customers,

Veracyte is honored to join the breast cancer community in recognizing Breast Cancer Awareness Month this year – and supporting more informed care for breast cancer patients throughout the year.

While we are new to breast cancer, as the new “owners” of the Prosigna® Breast Cancer Prognostic Gene Signature Assay, we are not new to the disease’s devastating impact on patients and those around them. Most of us have been touched – either directly or indirectly – by this disease, which is the most common cancer in women worldwide and, according to the World Health Organization, killed 625,000 women in 2018.

As a global genomic diagnostics company, Veracyte leverages genomic insights to improve patient care in cancer and other diseases– helping patients avoid unnecessary risky, costly procedures while accelerating time to appropriate treatment. Our initial tests are creating new standards of care in thyroid cancer, lung cancer and idiopathic pulmonary fibrosis.

We are honored to be able to bring new advances in precision medicine to bear in the fight against breast cancer with the Prosigna classifier. This test is uniquely designed to inform treatment decisions for the majority of early-stage breast cancer patients.

We are also excited by emerging data suggesting the ability of the genomic signature on which the Prosigna test is based to help inform which patients with early-stage, high-risk breast cancer may potentially benefit from new targeted therapies. We look forward to working with the breast cancer research community to advance understanding about the role of genomic testing in breast cancer clinical practice and in opportunities to further improve patient care and outcomes.

As Veracyte “goes pink” for Breast Cancer Awareness Month, we and our employees look forward to engaging in a number of activities to support the breast cancer community. And, importantly, we commit that our work to help breast cancer patients and the physicians who care for them will continue all year long.

Warm regards,

signature CEO

Bonnie Anderson
Chairman and CEO

Prosigna logo

Uniquely designed to inform treatment decisions
for the majority of early stage breast cancer patients

Learn more about the Prosigna Classifier.
877-754-6124 or